Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257348 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00257348 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 5 participants.
The verdict
NCT00257348, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effectiveness and side effects of the drugs capecitabine and docetaxel in the treatment of cervical cancer. Capecitabine is approved by the FDA for the treatment of breast and colon cancer. Docetaxel is approved in the treatment of breast and lung cancer. The use of capecitabine and docetaxel in this study for the treatment of cervical cancer is considered investigational. Eligible subjects will take the drug capecitabine (Xeloda) by mouth twice a day every 12 hours, for fourteen consecutive days followed by a 7 day rest period. Subjects will also receive the drug docetaxel (Taxotere) intravenously (in the vein) every three weeks.
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257348
The ClinicalTrials.gov registry entry for NCT00257348 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00257348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257348 about?
NCT00257348 is a clinical study titled "Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer". The purpose of the study is to evaluate the effectiveness and side effects of the drugs capecitabine and docetaxel in the treatment of cervical cancer. Capecitabine is approved by the FDA for the treatment of breast and colon cancer. Docetaxel is approved in the treatment of breast and lung cancer. ...
What is the current status of trial NCT00257348?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2004-03. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00257348?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00257348?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.